Bayer Reports the Initiation of P-III (SOHO-02) Study of BAY 2927088 to Treat Non-Small Cell Lung Cancer (NSCLC)
Shots:
- The first patient has been dosed in P-III (SOHO-02) study assessing BAY 2927088 vs SoC (cisplatin/carboplatin + pemetrexed + Keytruda) as a 1L treatment of NSCLC with activating HER2 mutations. The 1EP is PFS with other EPs as ORR & DoR
- BAY 2927088 is also being evaluated as a 2L treatment for unresectable or metastatic NSCLC with activating HER2 (ERBB2) mutations in treatment-experienced adults. P-I/II (SOHO-01) study will be highlighted at the WCLC 2024
- BAY 2927088 (oral) is developed under Bayer’s partnership with the Broad Institute of MIT & Harvard. It is a reversible TKI that works by inhibiting mutant HER2 (incl. exon 20 insertions and point mutations) & EGFR, with high selectivity for mutant vs wild-type EGFR
Ref: Bayer | Image: Bayer
Related News:- Bayer’s BAY 2927088 Receives the USA FDA’s Break Through Designation for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
